Schwartz Investment Counsel Inc. Boosts Position in Regeneron Pharmaceuticals, Inc. $REGN

Schwartz Investment Counsel Inc. boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 975 shares of the biopharmaceutical company’s stock after purchasing an additional 175 shares during the quarter. Schwartz Investment Counsel Inc.’s holdings in Regeneron Pharmaceuticals were worth $512,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of REGN. Brighton Jones LLC boosted its position in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares in the last quarter. GAMMA Investing LLC boosted its position in Regeneron Pharmaceuticals by 41.8% during the first quarter. GAMMA Investing LLC now owns 1,286 shares of the biopharmaceutical company’s stock worth $816,000 after purchasing an additional 379 shares in the last quarter. Blue Trust Inc. boosted its position in Regeneron Pharmaceuticals by 18.2% during the first quarter. Blue Trust Inc. now owns 331 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 51 shares in the last quarter. Intact Investment Management Inc. boosted its position in Regeneron Pharmaceuticals by 56.0% during the first quarter. Intact Investment Management Inc. now owns 780 shares of the biopharmaceutical company’s stock worth $495,000 after purchasing an additional 280 shares in the last quarter. Finally, Kentucky Retirement Systems Insurance Trust Fund boosted its position in Regeneron Pharmaceuticals by 9.3% during the first quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 3,040 shares of the biopharmaceutical company’s stock worth $1,928,000 after purchasing an additional 259 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have commented on REGN shares. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research report on Monday, August 4th. Citigroup upped their price objective on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Finally, Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price objective on the stock. in a research report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $817.88.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $576.77 on Tuesday. The firm has a market capitalization of $61.13 billion, a P/E ratio of 14.54, a PEG ratio of 1.80 and a beta of 0.31. The stock has a fifty day moving average price of $575.25 and a 200 day moving average price of $562.14. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $991.23. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $11.56 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.